• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

弥漫性大 B 细胞淋巴瘤的蛋白质组学分析。

Proteomic Profiling of Diffuse Large B-Cell Lymphomas.

机构信息

Department of Oncology-Pathology, Karolinska Institutet Solna, Stockholm, Sweden.

Division of Oncology and Pathology, Department of Clinical Sciences, Faculty of Medicine, Lund University, Uppsala, Sweden.

出版信息

Pathobiology. 2018;85(4):211-219. doi: 10.1159/000486285. Epub 2018 Apr 4.

DOI:10.1159/000486285
PMID:29617697
Abstract

OBJECTIVE

The aim of this study was to identify differences in proteome profiles of diffuse large B-cell lymphoma (DLBCL) of nongerminal center (non-GC) versus GC type in the search for new markers and drug targets.

METHODS

Six DLBCL, with 3 repeats for each, were used for the initial study by proteomics: 3 non-GC and 3 GC DLBCL cases. For immunohistochemistry, tissue microarrays were made from 31 DLBCL samples: 16 non-GC de novo lymphomas and 15 GC cases (11 transformed from follicular lymphomas and 4 de novo GC lymphomas). Proteome profiling was performed by two-dimensional gel electrophoresis and MALDI-TOF mass spectrometry.

RESULTS

Ninety-one proteins were found differentially expressed in non-GC compared to GC type. The Cytoscape tool was used for systemic analysis of proteomics data, revealing 19 subnetworks representing functions affected in non-GC versus GC types of DLBCL.

CONCLUSION

A validation study of 3 selected proteins (BiP/Grp78, Hsp90, and cyclin B2) showed the enhanced expression in non-GC DLBCL, supporting the proteomics data.

摘要

目的

本研究旨在通过蛋白质组学研究,确定非生发中心(non-GC)与生发中心(GC)弥漫性大 B 细胞淋巴瘤(DLBCL)之间的蛋白质组图谱差异,以寻找新的标记物和药物靶点。

方法

采用蛋白质组学方法对 6 例 DLBCL 进行初始研究,每个类型重复 3 次:3 例非 GC 型和 3 例 GC 型 DLBCL。为进行免疫组织化学研究,从 31 例 DLBCL 样本中制作组织微阵列:16 例非 GC 初发性淋巴瘤和 15 例 GC 病例(11 例由滤泡性淋巴瘤转化而来,4 例为 GC 初发性淋巴瘤)。通过二维凝胶电泳和 MALDI-TOF 质谱进行蛋白质组分析。

结果

与 GC 型相比,非 GC 型发现有 91 种蛋白质表达差异。使用 Cytoscape 工具对蛋白质组学数据进行系统分析,揭示了 19 个代表非 GC 与 GC 型 DLBCL 中受影响功能的子网。

结论

对 3 种选定蛋白质(BiP/Grp78、Hsp90 和细胞周期蛋白 B2)的验证研究表明,非 GC DLBCL 中表达增强,支持蛋白质组学数据。

相似文献

1
Proteomic Profiling of Diffuse Large B-Cell Lymphomas.弥漫性大 B 细胞淋巴瘤的蛋白质组学分析。
Pathobiology. 2018;85(4):211-219. doi: 10.1159/000486285. Epub 2018 Apr 4.
2
Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter's Trans-Formed DLBCL and Germinal Center B-Cells.初诊弥漫性大 B 细胞淋巴瘤、转化滤泡性淋巴瘤、里希特转化弥漫性大 B 细胞淋巴瘤和生发中心 B 细胞中趋化因子受体表达谱的差异。
Int J Mol Sci. 2022 Jul 17;23(14):7874. doi: 10.3390/ijms23147874.
3
Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.225例初发弥漫性大B细胞淋巴瘤及276例其他B细胞淋巴瘤中异常T细胞标志物表达的临床及预后意义
Oncotarget. 2017 May 16;8(20):33487-33500. doi: 10.18632/oncotarget.16532.
4
Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.生发中心型弥漫性大B细胞淋巴瘤中Fas和Fas配体的表达与临床结局相关。
Eur J Haematol. 2006 Jun;76(6):465-72. doi: 10.1111/j.1600-0609.2006.00631.x. Epub 2006 Feb 23.
5
Quantitative proteomics analysis of differentially expressed proteins in activated B-cell-like diffuse large B-cell lymphoma using quantitative proteomics.采用定量蛋白质组学技术分析激活 B 细胞样弥漫性大 B 细胞淋巴瘤中差异表达蛋白。
Pathol Res Pract. 2019 Sep;215(9):152528. doi: 10.1016/j.prp.2019.152528. Epub 2019 Jul 6.
6
The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.t(14;18)与生发中心来源的弥漫性大B细胞淋巴瘤相关,并且是预后的有力预测指标。
Clin Cancer Res. 2003 Jun;9(6):2133-9.
7
Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma.弥漫性大B细胞淋巴瘤中Bcl-6与CD10的共表达:Bcl-6表达模式在鉴别生发中心B细胞淋巴瘤中的意义
Hum Pathol. 2001 Sep;32(9):954-62. doi: 10.1053/hupa.2001.27118.
8
Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis.类风湿关节炎中弥漫性大B细胞淋巴瘤的特征
Arthritis Rheum. 2006 Dec;54(12):3774-81. doi: 10.1002/art.22277.
9
Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases.生发中心和活化B细胞特征可区分艾滋病相关和非艾滋病相关病例中的伯基特淋巴瘤与弥漫性大B细胞淋巴瘤。
Am J Clin Pathol. 2005 Nov;124(5):790-8. doi: 10.1309/7CEA-WV0D-NLLU-WQTF.
10
Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy.接受免疫化疗的患者中,转化型和原发性弥漫性大B细胞淋巴瘤的预后相似。
Med Clin (Barc). 2017 Mar 22;148(6):243-249. doi: 10.1016/j.medcli.2016.09.050. Epub 2016 Dec 27.

引用本文的文献

1
Advances in lymphoma biomarkers research based on proteomics technology (Review).基于蛋白质组学技术的淋巴瘤生物标志物研究进展(综述)
Oncol Rep. 2025 Sep;54(3). doi: 10.3892/or.2025.8941. Epub 2025 Jul 4.
2
Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases?在血液肿瘤疾病中,HSP70 仍然可以作为治疗靶点吗?
Biomolecules. 2023 Mar 28;13(4):604. doi: 10.3390/biom13040604.
3
Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma.
基于 MS 的蛋白质组学研究的荟萃分析表明干扰素调节因子 4 和核结合蛋白 1 是弥漫性大 B 细胞淋巴瘤潜在的预后和耐药生物标志物。
Cells. 2023 Jan 3;12(1):196. doi: 10.3390/cells12010196.
4
Proteomic analysis of exposed to lead (Pb) stress reveal new proteins with potential roles in Pb tolerance and detoxification mechanism.对暴露于铅(Pb)胁迫下的蛋白质组学分析揭示了在铅耐受性和解毒机制中具有潜在作用的新蛋白质。
Front Plant Sci. 2022 Oct 20;13:1009756. doi: 10.3389/fpls.2022.1009756. eCollection 2022.